Tridek-One Alternatives & Competitors
12 companies similar to Tridek-One — We develop first-in-class CD31 checkpoint agonists for the treatment of auto-imm...
Companies similar to Tridek-One
Upstream Bio
Developing treatments for inflammatory diseases
Waltham, United States
Dianthus Therapeutics, Inc.
Building a leading biotech company focused in severe autoimmune diseases.
United States
ImCheck Therapeutics
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
Marseille, France
Azome Therapeutics
Developing selective NLRP3 inflammasome inhibitors for severe inflammatory diseases
Rival Readout
Competing with Tridek-One? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Asylia Therapeutics
Innovative therapies reshaping immune responses against autoimmune, cancer, and infectious...
BIORCHESTRA Co., Ltd.
We develop novel RNA-based therapeutics that will be able to bring about a paradigm shift...
Cambridge, United States
Georgiamune Inc.
Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fi...
Gaithersburg, United Stat...
Abcuro, Inc
Developing immunotherapies for autoimmune diseases and cancer
Evommune
Developing innovative therapies that target key drivers of chronic inflammatory diseases.
Palo Alto, United States
Adendra Therapeutics
Translating dendritic cell biology into new therapies for cancer and autoimmunity.
London, United Kingdom
3T Biosciences
3T is an immunotherapy company developing next-generation, transformative therapies for br...
South San Francisco, Unit...
About Tridek-One
Tridek-One is a French biotechnology startup founded in 2018, specializing in the development of first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases. The company's focus on anti-CD31 agonistic mAbs presents...
Development of first-in-class CD31 checkpoint agonists for the treatment of autoimmune and inflammatory diseases.
Patients with autoimmune and inflammatory diseases, healthcare providers, pharmaceutical companies, and biotech research institutions.
Immunomodulation, Therapeutic Antibodies, Autoimmune Diseases, Inflammatory Disorders, Biopharmaceuticals, Immunotherapy, Drug Development, Immune Checkpoint Modulation, Monoclonal Antibodies, Immunological Research, Therapeutic Innovation, Immune System Modulation, Clinical Development, Autoimmune Therapy
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Tridek-One: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Tridek-One on 7 Jun 2025. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
